12 35

Cited 0 times in

Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial

Authors
 Tae Hyung Kim  ;  Minkoo Kim  ;  Hyung Joon Yim  ;  Sang Jun Suh  ;  Young Kul Jung  ;  Yeon Seok Seo  ;  Soon Ho Um  ;  Jung Il Lee  ;  Sae Hwan Lee  ;  Sang Gyun Kim  ;  In Hee Kim  ;  Hyoung Su Kim  ;  Eun Young Cho  ;  Tae Yeob Kim and Seong Gyu Hwang 
Citation
 HEPATITIS MONTHLY, Vol.21(11) : e121627, 2021-11 
Journal Title
HEPATITIS MONTHLY
ISSN
 1735-143X 
Issue Date
2021-11
Keywords
Adefovir ; Hpatitis B ; Lamivudine Resistance ; Rescue Therapy ; Telbivudine
Abstract
Background: In countries with unavailable tenofovir, a combination of lamivudine (LMV) and adefovir (ADV) is recommended for the treatment of LMV-resistant chronic hepatitis B (CHB). Considering that telbivudine (L-dT) was demonstrated to be superior to LMV in previous studies, L-dT and ADV combination therapy is expected to show better antiviral efficacy than the combination of LMV and ADV in patients with LMV-resistant CHB.
Methods: This was a prospective randomized multicenter study. The primary endpoint was Hepatitis B Virus (HBV) DNA reduction after 52 weeks of treatment. The secondary endpoints were HBV DNA undetectability, hepatitis B e antigen seroconversion, the incidence of virological and biochemical breakthroughs, and safety during the study period.
Results: A total of 43 LMV-resistant CHB patients were enrolled. Twenty-one were treated with LMV + ADV and 22 with L-dT + ADV. After 52 weeks of antiviral treatment, the HBV DNA reduction showed no significant intergroup difference (-4.54 ± 1.23 log IU/mL in the LMV + ADV group, -4.24 ± 1.46 log IU/mL in the L-dT + ADV group, P = 0.475). There were no significant intergroup differences in HBV DNA undetectability rates, mean HBV DNA level, or hepatitis B e antigen seroconversion rate at 13, 26, 39, and 52 weeks of treatment. In terms of safety, the mean creatine phosphokinase level was significantly higher in the L-dT + ADV group.
Conclusions: In the treatment of LMV-resistant CHB, the combination of L-dT and ADV did not show any clinical benefit compared to the combination of LMV and ADV.
Files in This Item:
T992021125.pdf Download
DOI
10.5812/hepatmon.121627
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Jung Il(이정일) ORCID logo https://orcid.org/0000-0002-0142-1398
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/196689
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links